Prostatype Genomics AB (OSTO:PROGEN) 6-Month Price Index: 0.43 (As of Sep. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSTO:PROGEN Prostatype Genomics AB OSTO:PROGEN
12 GF Score
Price kr0.16
GF Value kr0.15
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Prostatype Genomics AB 6-Month Price Index?

Prostatype Genomics AB OSTO:PROGEN +1.92% 12 6-Month Price Index is 0.43 as of Sep. 16, 2026. GuruFocus rates OSTO:PROGEN with a GF Score™ of 12/100 and a GF Value™ of kr0.15 (Fairly Valued). The stock has 6 warning signs investors should review.

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2026-09-16), Prostatype Genomics AB's 6-Month Price Index is 0.43.

Prostatype Genomics AB  (OSTO:PROGEN) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Prostatype Genomics AB 6-Month Price Index Related Terms

OSTO:PROGEN vs TMO, DHR, NTRA: 6-Month Price Index Comparison

For the Diagnostics & Research subindustry, Prostatype Genomics AB's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OSTO:PROGEN
12GF Score
Prostatype Genomics AB OSTO:PROGEN
6-Month Price Index is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB  (OSTO:PROGEN) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about 6-Month Price Index →
What does a 6-Month Price Index of 0.43 mean?
Prostatype Genomics AB (OSTO:PROGEN) has a 6-Month Price Index of 0.43 as of Sep. 16, 2026. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's 6-Month Price Index too high?
Prostatype Genomics AB's current 6-Month Price Index is 0.43. Overall, Prostatype Genomics AB has a GF Score™ of 12/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's 6-Month Price Index compare to TMO and DHR?
Prostatype Genomics AB's 6-Month Price Index of 0.43 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 6-Month Price Index for a Medical Diagnostics & Research company?
A good 6-Month Price Index depends on the Medical Diagnostics & Research industry context. However, 6-Month Price Index should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 6-Month Price Index mean?
A high 6-Month Price Index can signal that a stock is expensive relative to its fundamentals. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current 6-Month Price Index is 0.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Based on GuruFocus' analysis, Prostatype Genomics AB (OSTO:PROGEN) is currently considered Fairly Valued. The stock's GF Value™ is kr0.15, compared to a current price of kr0.16 — trading 6% above its estimated fair value. The current 6-Month Price Index is 0.43. Prostatype Genomics AB's overall GF Score™ is 12/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 6-Month Price Index calculated?
6-Month Price Index is calculated from a company's financial statements. For Prostatype Genomics AB (OSTO:PROGEN), the current 6-Month Price Index is 0.43 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (OSTO:PROGEN) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of kr0.16 is trading 6% above its estimated GF Value™ of kr0.15. GuruFocus considers Prostatype Genomics AB to be Fairly Valued.

Key valuation signals for OSTO:PROGEN:

  • 6-Month Price Index: 0.43
  • GF Value™: kr0.15 vs. price of kr0.16 (6% above fair value)
  • GF Score™: 12/100 with 6 warning signs

No single metric tells the full story. See the OSTO:PROGEN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Other Exchanges PGO0:Germany
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
12GF Score

Get the complete analysis for OSTO:PROGEN

6-Month Price Index is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr0.16
Price
kr0.15
GF Value